Comparison 12. Withdrawals ‐ febuxostat 240 mg/day versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 TOTAL	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 28 weeks	1	268	Risk Ratio (M‐H, Fixed, 95% CI)	1.45 [1.00, 2.11]
2 Adverse event	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 28 weeks	1	268	Risk Ratio (M‐H, Fixed, 95% CI)	2.2 [0.79, 6.16]
3 Gout flare	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 28 weeks	1	268	Risk Ratio (M‐H, Fixed, 95% CI)	17.0 [0.99, 291.60]
4 Lack of efficacy	1		Risk Ratio (IV, Fixed, 95% CI)	Subtotals only
4.1 28 weeks	1	268	Risk Ratio (IV, Fixed, 95% CI)	0.67 [0.11, 3.93]
5 Other reasons	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 28 weeks	1	268	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.66, 1.76]